J2 Capital Management’s Gilead Sciences GILD Stock Holding History

J2 Capital Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$462K	Sell	3,660 -120	-3%	-$15.8K	0.31%	83
2026 Q1	$527K	Buy	3,780 +103	+3%	+$14.4K	0.36%	73
2025 Q4	$451K	Sell	3,677 -97	-3%	-$11.8K	0.33%	85
2025 Q3	$419K	Sell	3,774 -90	-2%	-$10.2K	0.32%	85
2025 Q2	$428K	Buy	3,864 +1,432	+59%	+$152K	0.34%	75
2025 Q1	$273K	Buy	+2,432	New	+$251K	0.25%	83

Other funds holding GILD

LMFP

Larry Mathis Financial Planning Phoenix, Arizona $124B AUM

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

CIM

Confluence Investment Management St. Louis, Missouri $6.4B AUM 9.79% 1-Year Est. Return

CGH

Crossmark Global Holdings Houston, Texas $7.71B AUM 37.66% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

CNB

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return

COPPSERS

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

J2 Capital Management's GILD Position: Q2 2026 in Review

J2 Capital Management reduced its Gilead Sciences (GILD) stake by 3.2% in Q2 2026, selling an estimated $15.8K and leaving 3,660 shares worth $462K. The position accounts for 0.31% of the portfolio, ranked #83.

J2 Capital Management first reported a position in GILD in Q1 2025 and has held it in 6 quarters since. The position peaked at $527K in Q1 2026. 425 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

J2 Capital Management held 3,660 shares of Gilead Sciences worth $462K as of Q2 2026.
J2 Capital Management sold 120 Gilead Sciences shares in Q2 2026, an estimated $15.8K.
Gilead Sciences made up 0.31% of J2 Capital Management's portfolio in Q2 2026, its #83 holding.
J2 Capital Management first reported a position in Gilead Sciences in Q1 2025 and has held it in 6 quarters since.
J2 Capital Management's Gilead Sciences position peaked at $527K in Q1 2026.
425 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on J2 Capital Management's 13F filing for Q2 2026, filed 20 Jul 2026.